

## appendix e-1

*HRM and Sanger Sequencing.* HRM was performed with the LightCycler 480 Real-Time PCR system and High Resolution Master Mix (Roche; Indianapolis, IN, USA). Reactions were performed in either 96- or 384-well plates, using 40 ng of template DNA, 1× HRM Master Mix, 2.5 mM MgCl<sub>2</sub>, and 200 nM of each primer in a 10-μl reaction volume. Melting curves and difference plots were analyzed by at least two investigators blinded to phenotype. Shifted melting curves were further investigated using ExoSAP-IT<sup>®</sup> (Affymetrix; Santa Clara, CA, USA)-cleaned PCR products and bidirectional Sanger sequencing.

*In Silico Analyses.* SIFT (<http://sift.jcvi.org/>) is a sequence homology-based tool that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino acid substitution at a particular position in a protein will have a phenotypic effect. MutationTaster (<http://www.mutationtaster.org>) applies a naïve Bayes classifier to data derived from evolutionary conservation, splice-site changes, loss of protein features and changes that might affect the amount of messenger RNA to predict disease potential. PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) predicts pathogenicity by applying a probabilistic classifier to sequence- and structure-based information. CADD (<http://cadd.gs.washington.edu/>) predicts pathogenicity of the variants from the whole genome by training a linear kernel support vector machine (SVM) to differentiate evolutionarily derived possibly benign alleles from simulated conceivably deleterious variants. CADD raw scores offer superior resolution across the entire spectrum of scores and are suggested for use in large case-control studies of single or multiple genes. In contrast, scaled CADD Scores (PHRED-like), which range from 0 to 99, may be most useful for identifying causal variants within an individual exome or genome. A scaled CADD score of 10 corresponds to the top 10% deleterious variants whereas a score of 20 corresponds to the top 1% of deleterious variants and so forth.

*Population Controls.* The EVS dataset is comprised of 2203 African-American and 4300 European-American unrelated individuals. The EVS cohort includes controls, extremes of specific traits such as cholesterol and blood pressure and specific diseases such as myocardial infarction and stroke. The 1KG cohort includes individuals of Asian, African and European ancestry. 1KG samples are mostly anonymous and have no associated phenotypic data. ExAC provides data on 60,706 unrelated individuals sequenced as part of various disease-specific and population genetic studies. In general, SVs reported in EVS, 1KG and ExAC have not been confirmed with bidirectional Sanger sequencing.

**Table e-1**  
**Clinical diagnoses and demographics for additional screening of TOR1A Exon 5**

Clinical diagnosis	Number (age of onset) <sup>a</sup>	Family history <sup>b</sup>	Gender		Race/Ethnicity			Sequence Variant (n) <sup>c</sup>
			Male	Female	Caucasian	Jewish	Other	
Spasmodic dysphonia	128 (48.8 ± 8.8, 13-80)	13.3%	40	88	114	2	12	
Cervical dystonia	319 (44.4 ± 7.1, 10 -85)	13.2%	77	242	301	5	13	c. 907_909delGAG (1)
Blepharospasm	145 (57.7 ± 5.2, 11-79)	7.6%	47	98	142	0	3	
Writer's cramp	13 (34.8 ± 13.2, 7-60)	7.7%	8	5	11	0	2	
Other primary focal dystonia	58 (44.1 ± 10.8, 1-84)	17.2%	18	40	51	1	6	
Segmental dystonia	85 (44.1 ± 8.6, 5-78)	18.8%	23	62	73	0	12	c.962C>T (1)
Multifocal & generalized	24 (22.2 ± 9.9, 1-68)	33.3%	7	17	18	3	3	c. 907_909delGAG (2)
<b>Dystonia totals</b>	<b>772</b> <b>(46.7 ± 10.0, 1-85)</b>	<b>13.6%</b>	<b>220</b>	<b>552</b>	<b>710</b>	<b>11</b>	<b>51</b>	
Other movement disorders	214 (48.4 ± 10.6, 1-76)	NA	102	112	189	3	22	
Neurologically- normal controls	174 (53.3 ± 10.1, 18-87) <sup>d</sup>	NA	68	106	118	2	56	
<b>Grand total</b>	<b>1160</b>							

<sup>a</sup>Mean +/- standard error, range (yrs).

<sup>b</sup>First- or second-degree relative with dystonia.

<sup>c</sup>(n) - number of subjects with identified SV

<sup>d</sup>Age at study enrollment.

NA = not available or applicable.

**Table e-2**  
**Primers for Sanger Sequencing and High Resolution Melting**

<b>Primer</b>	<b>Sequence (5'→3')</b>	<b>Locus</b>	<b>Exon</b>	<b>Product (bp)</b>
<b>GNAL_E1aF</b>	aatgcaaatgaccctctgg	NC_000018 11689089-109		
<b>GNAL_E1aR</b>	ccggggcgtcagccgac	NC_000018 11689973-957	Exon 1a	885 (with GNAL_E1aF)
<b>GNAL_E2F</b>	cctgctctgaatcggaaac	NC_000018 11752280-299		
<b>GNAL_E2R</b>	atttctacacgcgggttc	NC_000018 11752751-733	Exon 2	472 (with GNAL_E2F)
<b>GNAL_E3F</b>	ccggctagtggtagagatg	NC_000018 11752783-802		
<b>GNAL_E3R</b>	aagcacttttgggacgtctg	NC_000018 11752995-976	Exon 3	213 (with GNAL_E3F)
<b>GNAL_E4F</b>	ggaaatttaaatcccactcaa	NC_000018 11753547-568		
<b>GNAL_E5R</b>	aaaatggttccatcttctact	NC_000018 11753995-975	Exons 4 & 5	449 (with GNAL_E4F)
<b>GNAL_E6F</b>	tttcagttcttttctcttt	NC_000018 11824835-856		
<b>GNAL_E6R</b>	tgatgcaatcatattcttcaa	NC_000018 11825069-048	Exon 6	235 (with GNAL_E6F)
<b>GNAL_E7F</b>	gggaaagtgggagagaaac	NC_000018 11862344-362		
<b>GNAL_E7R</b>	tctcaaagtttctgtgtgtgg	NC_000018 11862493-472	Exon 7	150 (with GNAL_E7F)
<b>GNAL_E8F</b>	atacccggtcttaccttga	NC_000018 11864464-483		
<b>GNAL_E8R</b>	gaagccccctaaacctcac	NC_000018 11864687-668	Exon 8	224 (with GNAL_E8F)
<b>GNAL_E9F</b>	atgtgtgaacgtggaacct	NC_000018 11867062-081		
<b>GNAL_E9R</b>	tgctgagtgttagaattcactcc	NC_000018 11867278-256	Exon 9	217 (with GNAL_E9F)
<b>GNAL_E10F</b>	ctgagtagctgctgggtgtg	NC_000018 11868457-476		
<b>GNAL_E10R</b>	cctggcctgagcgtatttt	NC_000018 11868736-718	Exon 10	280 (with GNAL_E10F)
<b>GNAL_E11F</b>	ctatgttagagcacttctatg	NC_000018 11872201-222		
<b>GNAL_E11R</b>	aaacaattctattcctcaatcat	NC_000018 11872443-421	Exon 11	570 (with GNAL_E11F)
<b>GNAL_E12F</b>	ccttctgttttcgtagagttg	NC_000018 11876547-569		
<b>GNAL_E12R</b>	gaaggaggtagaaaaacaagg	NC_000018 11876727-705	Exon 12	181 (with GNAL_E12F)
<b>GNAL_E13F</b>	tcctccccagagtacatgc	NC_000018 11880928-947		
<b>GNAL_E13R</b>	agagactctgcctcctaccat	NC_000018 11881218-198	Exon 13	291 (with GNAL_E13F)
<b>THAP1_E1F</b>	aagaagcgagggaatccaac	NT_007995 13018721-702		
<b>THAP1_E1R</b>	ccccaccggctgaga	NT_007995 13018509-525	Exon 1	213 (with THAP1_1F)
<b>THAP1_E2F</b>	tttgggtgcctttattttt	NT_007995 13014975-955		
<b>THAP1_E2R</b>	caaaaagcaaccaatatttta	NT_007995 13014683-704	Exon 2	293 (with THAP1_2F)
<b>THAP1_E3F</b>	tggtcagtccacagattcttt	NT_007995 13013940-919		
<b>THAP1_E3R</b>	tgtggtattgccccattaga	NT_007995 13013452-471	Exon 3	489 (with THAP1_3F)
<b>TOR1A_E5F</b>	cagcacctgtttcttctcc	NC_000009 132576505-525		
<b>TOR1A_E5R</b>	ccaactccaggcagtgactc	NC_000009 132576212-231	Exon 5	283 (with TOR1A_5F)